上海莱士(002252.SZ)：目前，广西莱士处于试生产阶段

Core Viewpoint - The company is currently in the trial production phase for its Guangxi Laishi project, which is expected to enhance production capacity upon completion of drug registration and approval processes [1] Group 1: Company Progress - Guangxi Laishi is in the trial production stage and will gradually increase output after completing trial production and drug registration approval [1] - The company aims to expedite the approval process for Guangxi Laishi products to achieve stable operations [1] Group 2: Industry Context - The blood products industry has unique characteristics, with production primarily influenced by plasma collection capabilities and regulatory approval of drugs [1]